Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study.

What Was Tested

Researchers studied Amides in this randomized controlled trial publication.

The aim of this study was to investigate the effect of aliskiren on hard renal endpoints, when added to an ARB, in patients with advanced chronic kidney disease (CKD).

Why It Was Studied

However, it remains unclear whether this combination therapy contributes to suppression of kidney disease progression.

Who Took Part

The study group was 83 patients.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

The study design was a prospective, randomized open-label design. 83 CKD patients (52 men and 31 women) were enrolled and assigned randomly to an aliskiren add-on group (n = 42) or control group (n = 41).

All participants were treated with an ARB.

How the Study Was Run

In design terms this was a randomized and open-label study.

The patients were allocated by chance, so the Amides group and the comparison group should start out alike.

Nothing was hidden in this open-label Amides study: the patients and staff both knew the treatment.

The follow-up period was 12 months. 12 participants were withdrawn during the study period and the study was terminated in January 2012 as a consequence of the results of the interim analysis of the ALTITUDE study.

What Was Measured

Topics PubMed links to this paper include Amides, Angiotensin Receptor Antagonists, Fumarates, Kidney, Kidney Failure, Chronic and Renin Inhibitors.

What This Means in Plain Language

The paper is a randomized and open-label study of Amides in 83 patients.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2015 (Clinical and experimental nephrology), a journal based in Japan.

More context: all human trials.